Updated:
Xenon Pharmaceuticals
Xenon Pharmaceuticals was founded in 1996 by Dr. Michael Hayden and Dr.
Xenon Pharmaceuticals
Xenon Pharmaceuticals was founded in 1996 by Dr. Michael Hayden and Dr. Robert Young, built on the insight that rare genetic mutations causing extreme pain or seizure disorders illuminate drug targets with outsized therapeutic potential. The company's foundational discovery — a family in Newfoundland bearing a mutation in the SCN9A gene that abolished pain sensation — gave Xenon a genetic roadmap for Nav1.7 sodium channel inhibition. That lineage underpins a clinical pipeline that has outlasted most ion channel peers. Xenon operates as a clinical-stage biotechnology company, not a traditional allocator. Its assets span small-molecule and biologic candidates, with a disclosed focus on epilepsy and major depressive disorder (MDD). The lead program, azetukalner (XEN1101), is a Kv7 potassium channel opener that completed a Phase 3 program in focal onset seizures and advanced into a Phase 3 MDD study. A second epilepsy candidate, XEN496, targets KCNQ2 developmental and epileptic encephalopathy. The firm's partnerships have included Neurocrine Biosciences (pre-2019) and a long-running academic collaboration with the University of British Columbia. Geographic focus is North America, with clinical operations concentrated in the US and Canada. Xenon has historically operated with a lean team of under 200 employees, drawing on contract research organizations for trial execution. In September 2024 the company reported positive Phase 3 data for azetukalner in focal epilepsy, triggering a commercial build-out and the hiring of Chris Von Seggern as Chief Commercial Officer. The balance sheet carried roughly $500 million in cash and equivalents at year-end 2024, funding operations into 2027 without near-term dilution. A Boston office supplements the Burnaby, BC headquarters, housing business development and executive leadership. Unlike platform-agnostic biotechs that in-license late-stage assets, Xenon's structural differentiation is its insistence on genetically validated, ion channel–specific targets sourced from human phenotype data — a model that reduces biology risk but demands patience through long development cycles. The firm's succession from founder-led science to a commercially oriented leadership group under Ian Mortimer, who joined in 2013 and became CEO in 2015, marks a rare smooth transition in founder-driven biotech.
General information
Firm type
Asset Manager
Year founded
1996
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Burnaby
Corporate office
Burnaby, British Columbia, Canada
Additional offices
Boston, MA, United States
Principals
Ian Mortimer
President and Chief Executive Officer
Sherry Aulin
Chief Financial Officer
Chris Von Seggern
Chief Commercial Officer
Sector focus
Frequently asked questions
Who runs investment and capital allocation decisions at Xenon?
Capital allocation is led by CEO Ian Mortimer and CFO Sherry Aulin. Xenon is not a family office or fund — it is a publicly traded clinical-stage biotechnology company (NASDAQ: XENE). Decisions on equity financings, partnership structures, and balance-sheet deployment are approved by the board of directors. The firm last raised public equity in 2021, pricing a follow-on offering at $28 per share.
What is Xenon's core therapeutic focus and why does it matter?
Xenon targets ion channels, specifically sodium and potassium channels implicated in epilepsy and pain. The firm builds candidates around rare human genetic mutations — such as the SCN9A loss-of-function mutation identified in a Newfoundland family with congenital insensitivity to pain — that validate the target before a molecule enters the clinic. This human-genetics gate lowers biology risk relative to targets identified only in animal models.
How is Xenon different from other epilepsy-focused biotech companies?
Most epilepsy biotechs pursue broad-spectrum anticonvulsants or reformulations of existing mechanisms. Xenon is one of the few companies exclusively built around ion channel targets validated by human genotype-phenotype data. Its lead asset, azetukalner, is a Kv7.2/Kv7.3 potassium channel opener — a mechanism chemically distinct from the sodium-channel blockers that dominate the epilepsy market.
What does Xenon's partnership history tell allocators about its negotiating posture?
Xenon has historically retained global rights to its core pipeline. A 2012 deal with Genentech on Nav1.7 inhibitors returned rights to Xenon in 2017 after clinical discontinuation. A pre-2019 arrangement with Neurocrine Biosciences on an early-stage Nav1.2/Nav1.6 program was terminated by Xenon. The firm's balance-sheet strength, with roughly $500 million in cash at end-2024, allows it to advance programs without forced partnerships.
What are the key regulatory catalysts for Xenon's pipeline?
Azetukalner (XEN1101) is the primary value driver. The firm submitted an NDA for focal onset seizures in 2025, with an expected PDUFA date in 2026. A Phase 3 trial in major depressive disorder is ongoing and represents the largest indication expansion opportunity. A pediatric program for KCNQ2-related epilepsy under XEN496 has received FDA Rare Pediatric Disease Designation, providing a separate regulatory pathway with priority review voucher eligibility.
What is Xenon's cash runway and dilution posture?
As of December 31, 2024, Xenon reported cash, cash equivalents, and marketable securities of approximately $500 million. Management has guided that this funds operations into 2027, covering the azetukalner launch and ongoing MDD studies. The firm has historically been patient-capital friendly, with insiders holding meaningful equity and no aggressive secondary-selling history.
Does Xenon maintain any philanthropic or patient-access structures?
Xenon does not maintain a standalone philanthropic foundation, but the firm participates in rare-disease patient advocacy through its KCNQ2 patient community work. The pediatric KCNQ2 program was developed in close consultation with patient foundations, and the Rare Pediatric Disease Designation carries incentives intended to accelerate access for ultra-rare patient populations.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: